Based on this biological relevance of the cMET axis in UM as well as our preclinical data supporting the anti-migratory and anti-tumor activity of MET inhibition, we performed a phase II clinical trial to investigate our hypothesis that MET inhibition with crizotinib would prevent the establishment and development of metastases in patients with high-risk primary UM. Here, MET is linked to neoplasm.